Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics has announced a partnership with PhaseV to leverage advanced causal machine learning for their upcoming Phase 3 ALS trial, aiming to enhance study design and patient outcomes. Utilizing insights from PhaseV’s analysis of NeuroSense’s positive Phase 2b trial data, the collaboration seeks to optimize the Phase 3 trial for their ALS drug candidate, PrimeC. The company is preparing to discuss the updated Phase 3 study protocol with the FDA and EMA, following promising results in slowing disease progression among ALS patients.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.